Literature DB >> 17266571

The therapeutic potential of statins in neurological disorders.

G K Rajanikant1, D Zemke, M Kassab, A Majid.   

Abstract

Statins are currently among the most commonly prescribed agents for the prevention of cardiovascular disease. Statins reduce serum cholesterol levels by reversibly inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, in the nanomolar range. Mounting evidence suggests that in addition to their vascular effects such as stabilization of atherosclerotic plaques and decreased carotid intimal-medial thickness, statins have additional properties such as endothelial protection via actions on the nitric oxide synthase system as well as antioxidant, anti-inflammatory and anti-platelet effects. These effects of statins might have potential therapeutic implications in various neurological disorders such as stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis and primary brain tumors. In this review, the major protective mechanisms of statins and their applicability to the treatment of neurological disease are summarized. Although further experiments are required, currently available data would seem to indicate that clinical trials to determine the safety and efficacy of statins in a number of disorders are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266571     DOI: 10.2174/092986707779313462

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  17 in total

1.  Ipsilateral Infarct in Newly Diagnosed Cervical Internal Carotid Artery Atherosclerotic Occlusion.

Authors:  Diogo C Haussen; David Z Rose; Doniel Drazin; Scott D Newsome; Hannah Gardener; Randall C Edgell; Alan Boulos; Gary Bernardini; Tatjana Rundek; Dileep R Yavagal
Journal:  Interv Neurol       Date:  2015-07

Review 2.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

3.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome.

Authors:  G J Patti; L P Shriver; C A Wassif; H K Woo; W Uritboonthai; J Apon; M Manchester; F D Porter; G Siuzdak
Journal:  Neuroscience       Date:  2010-07-27       Impact factor: 3.590

Review 5.  Isoprenoids, small GTPases and Alzheimer's disease.

Authors:  Gero P Hooff; W Gibson Wood; Walter E Müller; Gunter P Eckert
Journal:  Biochim Biophys Acta       Date:  2010-04-08

6.  Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment.

Authors:  May A Beydoun; Lori L Beason-Held; Melissa H Kitner-Triolo; Hind A Beydoun; Luigi Ferrucci; Susan M Resnick; Alan B Zonderman
Journal:  J Epidemiol Community Health       Date:  2010-09-14       Impact factor: 3.710

7.  Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration.

Authors:  Ilse S Pienaar; Timothy Schallert; Suzél Hattingh; William M U Daniels
Journal:  J Neural Transm (Vienna)       Date:  2009-06-06       Impact factor: 3.575

8.  Simvastatin inhibited the apoptosis of PC12 cells induced by 1-methyl-4-phenylpyridinium ion via inhibiting reactive oxygen species production.

Authors:  Xudong Xu; Wenming Gao; Shanshan Dou; Baohua Cheng
Journal:  Cell Mol Neurobiol       Date:  2012-08-07       Impact factor: 5.046

Review 9.  Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy.

Authors:  Brahmanaidu Parim; V V Sathibabu Uddandrao; Ganapathy Saravanan
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

10.  Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.

Authors:  Pazit Bar-On; Leslie Crews; Andrew O Koob; Hideya Mizuno; Anthony Adame; Brian Spencer; Eliezer Masliah
Journal:  J Neurochem       Date:  2008-01-28       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.